Costs of treating patients with schizophrenia who have illness-related crisis events

BMC Psychiatry

Volumn 8, Issue , 2008, Pages

  Zhu, Baojin ^a   Ascher Svanum, Haya ^a   Faries, Douglas E ^a   Peng, Xiaomei ^a   Salkever, David ^b   Slade, Eric P ^c,d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; BEHAVIOR DISORDER; CASE MANAGEMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMMUNITY MENTAL HEALTH CENTER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; CRIMINAL BEHAVIOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COST; EMERGENCY CARE; FEMALE; HEALTH CARE SYSTEM; HOSPITALIZATION COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MENTAL HOSPITAL; MENTAL STRESS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; PSYCHOSOCIAL CARE; PSYCHOSOCIAL REHABILITATION; PSYCHOTHERAPY; SCHIZOPHRENIA; SUBSTANCE ABUSE; SUICIDE ATTEMPT; UNITED STATES; VIOLENCE; ADDICTION; COST; DEMOGRAPHY; ECONOMICS; GOVERNMENT; HEALTH CARE COST; HOSPITAL; HOSPITALIZATION; MENTAL HEALTH SERVICE; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGY; STATISTICS;

ADULT; COSTS AND COST ANALYSIS; DEMOGRAPHY; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HOSPITALS; HUMANS; MALE; MENTAL HEALTH SERVICES; PROSPECTIVE STUDIES; PSYCHOLOGY; SCHIZOPHRENIA; STRESS DISORDERS, POST-TRAUMATIC; SUBSTANCE-RELATED DISORDERS; SUICIDE, ATTEMPTED; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VIOLENCE;

EID: 51949108502     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-8-72     Document Type: Article

References (32)

1. Andlin-Sobocki P Jönsson B Wittchen HU Olesen J: Cost of disorders of the brain in Europe. Eur J Neurol 2005, 12(Suppl 1): 1-27. 10.1111/ j.1468-1331.2005.01202.x 15877774
2. Fanous AH Oord van den EJ Riley BP Aggen SH Neale MC O'Neill FA Walsh D Kendler KS: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005, 162:1824-1832. 10.1176/appi.ajp.162.10.1824 16199828
3. Weiden PJ Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419-429. 7481573
4. Gilmer TP Dolder CR Lacro JP Folsom DP Lindamer L Garcia P Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699. 10.1176/appi.ajp.161.4.692 15056516
5. Knapp M King D Pugner K Lapuerta P: Non-adherence to antipsychotic medication regimens: Associations with resource use and costs. Br J Psychiatry 2004, 184:509-516. 10.1192/bjp.184.6.509 15172945
6. Gibson PJ Damler R Jackson EA Wilder T Ramsey JL: The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004, 7:22-35. 10.1111/ j.1524-4733.2004.71272.x 14720128
7. Carr VJ Lewin TJ Neil AL Halpin SA Holmes S; Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. Br J Psychiatry 2004, 184:517-525. 10.1192/bjp.184.6.517 15172946
8. Almond S Knapp M Francois C Toumi M Brugha T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004, 184:346-351. 10.1192/bjp.184.4.346 15056580
9. Haro JM Novick D Suarez D Alonso J Lépine JP Ratcliffe M: SOHO Study Group Remission and relapse in the outpatient care of schizophrenia: Three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006, 26:571-578. 10.1097/ 01.jcp.0000246215.49271.b8 17110813
10. Moeller KE Shireman TI Liskow BI: Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006, 67:1942-1947. 17194273
11. Sernyak MJ Rosenheck R: Risk adjustment in studies using administrative data. Schizophr Bull 2003, 29:267-271. 14552502
12. Ettner SL Frank RG McGuire TG Hermann RC: Risk adjustment alternatives in paying for behavioral health care under Medicaid. Health Serv Res 2001, 36:793-811. 1089257 11508640
13. Frank RG McGuire TG Bae JP Rupp A: Solutions for adverse selection in behavioral health care. Health Care Financ Rev 1997, 18:109-122. 10170344
14. Dickey B Azeni H: Persons with dual diagnoses of substance abuse and major mental illness: Their excess costs of psychiatric care. Am J Public Health 1996, 86:973-977. 1380438 8669521
15. Mojtabai R Herman D Susser ES Sohler N Craig TJ Lavelle J Bromet EJ: Service use and outcomes of first-admission patients with psychotic disorders in the Suffolk County Mental Health Project. Am J Psychiatry 2005, 162:1291-1298. 10.1176/appi.ajp.162.7.1291 15994711
16. Ascher-Svanum H Zhu B Faries D Ernst FR: A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004, 3:11. 428579 15175112 10.1186/1475-2832-3-11
17. Salkever DS Slade EP: Employment retention by persons with schizophrenia employed in non-assisted jobs. Journal of Rehabilitation 2003, 69:18-25.
18. Salkever DS Slade EP Karakus M Palmer L Russo P: Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis 2004, 192:119-128. 10.1097/01.nmd.0000110283.89270.23 14770056
19. Lehman AF Fischer EP Postrado L Delahanty J Johnstone BM Russo PA Crown WH: The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003, 29:247-256. 14552500
20. Vaul JH: DRG benchmarking study establishes national coding norms. Healthc Financ Manage 1998, 52(5):52-54. 10179440
21. Hsiao WC Braun P Dunn D Becker ER: Resource-based relative values. An overview. JAMA 1988, 260:2347-2353. 10.1001/jama.260.16.2347 3050169
22. Good P: PermuAation tests: a practical guide to resampling methods of testing hypotheses New York (NY): Spring-Verlag 2000
23. Altman D: Practical statistics for medical research New York: Chapman & Hall/CRC 1999:126-130.
24. SAS Institute Inc SAS/STAT user's guide, version 8 Cary, NC: SAS Institute, Inc 1999 1
25. Lacro JP Dunn LB Dolder CR Leckband SG Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909. 12416599
26. Ascher-Svanum H Zhu B Faries D Lacro JP Dolder CR: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006, 67:1114-1123. 16889456
27. Svarstad BL Shireman TI Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001, 52:805-811. 10.1176/appi.ps.52.6.805 11376229
28. Valenstein M Copeland LA Blow FC McCarthy JF Zeber JE Gillon L Bingham CR Stavenger T: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630-639. 10.1097/00005650-200208000-00002 12187177
29. Ascher-Svanum H Faries DE Zhu B Ernst FR Swartz MS Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67:453-460. 16649833
30. Swartz MS Wagner HR Swanson JW Stroup TS McEvoy JP McGee M Miller del D Reimherr F Khan A Cañive JM Lieberman JA: Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006, 57:1110-1116. 10.1176/ appi.ps.57.8.1110 16870961
31. Fitzgerald PB Montgomery W de Castella AR Filia KM Filia SL Christova L Jackson D Kulkarni J: Australian Schizophrenia Care and Assessment Programme: Real-worlE schizophrenia: economics. Aust N Z J Psychiatry 2007, 41:819-829. 10.1080/00048670701579025 17828655
32. Kashner TM Rush AJ Crismon ML Toprac M Carmody TJ Miller AL Trivedi MH Wicker A Suppes T: An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. Psychiatr Serv 2006, 57:648-59. 10.1176/ appi.ps.57.5.648 16675759